334
Pediatric Crohn’s disease (cont.)
dose optimization, 165
endoscopic lesion severity scores, 164
immunomodulatory therapy, 165
incidence, 166
induction infliximab therapy, 166
infliximab, 163–167
maintenance therapy, 165
medication administration, 164
perianal disease, 167
Pediatric ulcerative colitis, infliximab,
167–169
Peripheral arthritis, 50
Pharmacodynamics
anti-TNFs, 2, 3
ustekinumab, 7
vedolizumab, 5, 6
Pharmacokinetics (pK), 115–117
anti-TNFs, 4, 5
biologic therapies, 114, 115
drug levels, clinical impact
anti-integrins, 117
certolizumab pegol, 117
ELISAs, 116
endoscopic healing, 116
endoscopic improvement, 116
indetectable infliximab levels, 116
infliximab drug levels, 116
mucosal healing, 116
nonscheduled dosing, 116
non-standardized timing, 116
serum concentrations, 115, 117
serum golimumab levels, 117
thiopurine therapy discontinuation, 116
ustekinumab, 7, 8
vedolizumab, 6
Physician global assessment (PGA), 165
Placental transfer, biologic agents, 83, 84
Pneumocystis carinii pneumonia (PCP)
infection, 195
Pneumocystis jiroveci pneumonia, 195
Postoperative prophylaxis, 71, 72, 74
Postoperative recurrence (POR), CD, 66–75
anastomotic technique, 65, 66
CRP levels, 62
disease behavior, 65
endoscopic recurrence, 59–61, 71
fecal calprotectin, 61, 62
immune-modifying therapies, 59
molecular markers, 75
patient-specific factors, 63, 64
postoperative medical management, 75
prevention
adalimumab, 70
biologic agents, 68–71
budesonide, 68
certolizumab pegol, 71
immunomodulators, 67
immunosuppressives, 69
infliximab, 69
medical therapy, 66
metronidazole, 67
nitroimidazole, 67
non biologic treatment, 66–68
oral mesalamine, 69
pharmacologic interventions, 70, 71
prophylactic infliximab, 68
thiopurines, 69
ustekinumab, 71
vedolizumab, 71
surgical specimen, 66
treatment methods
clinical guidelines, 75
disease recurrence, 75
early postoperative medical
prophylaxis, 74
endoscopic disease, 72
endoscopic findings of recurrence, 74
endoscopy-guided therapy, 74
medication initiation, 74
POCER study methods, 73
postoperative prophylaxis, 71
postoperative use, 72
prophylactic treatment, 73
ultrasound, 63
Preconception counseling, 82
Pregnancy, 82, 84–91
adverse outcomes, 82
anti-TNF agents
adalimumab, 82, 85
certolizumab pegol, 82, 86
clinical studies, 86–88
disease remission, 90
dosing schedule, 90, 91
golimumab, 86
with immunomodulators, 88
infliximab, 82, 84, 85
on newborns, 89, 90
complications, 81
exclusion criteria, 81
Preoperative biologic therapy, 138
Primary prophylaxis, 236
Primary sclerosing cholangitis (PSC), 53
Proactive drug monitoring, 122, 123
Progressive multifocal leukoencephalopathy
(PML), 114, 287, 288Index